. 2014 Nov 6;10:615–625. doi: 10.2147/VHRM.S56056

Table 1.

Recommended treatment strategies for hypercholesterolemia

	2001 Advanced Treatment Panel III/National Cholesterol Education Program guidelines⁷⁷,⁷⁸	2013 American College of Cardiology/American Heart Association guidelines⁷⁹,⁸⁰
Populations treated	1. Adults with CHD or CHD risk equivalents and LDL-C >100 mg/dL 2. Adults with 2+ CHD risk factors (10-year risk 10%–20%) and LDL-C >130 mg/dL 3. Adults with 2+ CHD risk factors (10-year risk <10%) and LDL-C >160 mg/dL 4. Adults with 0–1 CHD risk factors and LDL-C >190 mg/dL	1. Adults with clinical atherosclerotic cardiovascular disease 2. Adults with primary elevations of LDL-C >190 mg/dL 3. Adults with diabetes, aged 40–75 years, with LDL-C 70–189 mg/dL and without clinical ASCVD 4. Adults without clinical ASCVD or diabetes with LDL-C 70–189 mg/dL and estimated 10-year ASCVD risk >7.5%
Risk assessment method	LDL-C and CHD risk factor assessment based on Framingham data	CVD risk factor assessment based on pooled CVD data including total cholesterol
10-year risk calculator	Framingham⁸¹	Pooled cohort equations⁸²
Recommended treatments	Lifestyle modification with addition of cholesterol-lowering medications (primarily statins) based on LDL cholesterol and risk category	Statin cholesterol-lowering medications for all groups with statin therapy intensity determined based on risk category alone plus lifestyle modification
Treatment monitoring	Yes, treat to recommended LDL levels	Yes, treat independently of observed LDL levels
Recommended adult	Total: 43.2 million people (37.5%)	Total: 56.0 million (48.6%)
United States treatment	Aged 40–59 years: 20.3 million people (27.0%)	Aged 40–59 years: 22.3 million (29.7%)
population (2010)¹⁸	Aged 60–75 years: 13.5 million people (47.8%)	Aged 60–75 years: 21.9 million (77.3%)

Abbreviations: CHD, coronary heart disease; LDL-C, low-density lipoprotein cholesterol; ASCVD, arteriosclerotic cardiovascular disease; CVD, cardiovascular disease; LDL, low-density lipoprotein.